GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$44.98 USD
+0.10 (0.22%)
Updated May 17, 2024 04:00 PM ET
After-Market: $44.98 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth B Momentum A VGM
Price, Consensus and EPS Surprise
GSK 44.98 +0.10(0.22%)
Will GSK be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for GSK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GSK
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
Moderna (MRNA) Falls as FDA Extends Review Time for RSV Vaccine
GSK: What are Zacks experts saying now?
Zacks Private Portfolio Services
3 Top Dividend Stocks to Maximize Your Retirement Income
Here's Why GSK (GSK) is a Strong Value Stock
Here's Why GSK (GSK) is a Strong Value Stock
Other News for GSK
Novo Nordisk, J&J lead R&D rankings in big pharma: report
GSK to Divest Final Shares in Haleon
GSK Completely Exits Sensodyne Toothpaste Maker Haleon In $1.6B Sale
GSK sale of remaining Haleon stake nets more than $1.5B
LONDON MARKET MIDDAY: FTSE 100 slides; Eurozone inflation steady